Pharmacists Advocate for Transparency and Reform in Drug Pricing Following Trump Management Proposal
The Trump administration’s recent proposal too overhaul drug pricing,aiming for greater transparency and lower costs,has been met with cautious optimism from pharmacy advocates. B.Douglas Hoey,representing the interests of community pharmacists,voiced support for the plan’s focus on bringing accountability to Pharmacy Benefit Managers (PBMs) and health insurance companies,while simultaneously stressing the crucial role local pharmacists play in patient care and the need for broader legislative reforms. https://www.ncpa.co/newsroom/news-releases/2020/02/06/ncpa-statement-trump-administration-drug-pricing-proposal
The core of the administration’s plan centers on eliminating “kickbacks” and hidden fees within the pharmaceutical supply chain, especially those involving PBMs – the often-opaque intermediaries between drug manufacturers, insurance plans, and pharmacies.These pbms negotiate drug prices and create formularies (lists of covered drugs), wielding significant influence over which medications patients can access and at what cost.
the Problem with PBMs: A Lack of Transparency
For decades, PBMs have operated with limited public scrutiny, leading to concerns about conflicts of interest and inflated drug prices.Their business model often relies on rebates negotiated with drug manufacturers – discounts offered in exchange for preferential placement on formularies. While seemingly beneficial, these rebates aren’t always passed on to patients at the pharmacy counter. Instead, they are frequently retained by PBMs and insurance companies, contributing to higher premiums and out-of-pocket costs. https://www.pbs.org/newshour/health/pharmacy-benefit-managers-are-under-fire-for-driving-up-drug-costs
“They’ve operated in the shadows for decades and they’ve contributed more to the soaring cost of drugs than any othre actors in the industry,” Hoey stated, echoing a sentiment shared by many in the healthcare sector. The lack of transparency makes it tough to determine the true cost of a drug and whether patients are receiving the best possible price.
The administration’s proposal aims to address this by requiring PBMs to disclose the actual net price of drugs after rebates, possibly forcing them to pass on more savings to consumers. The “TrumpRx” component, which proposes removing PBMs from the equation altogether, is also viewed favorably by pharmacy advocates, though with reservations.
The Vital Role of the Local Pharmacist
While streamlining the drug supply chain through PBM removal could lower prices, Hoey cautioned against eliminating the crucial role of the local pharmacist. “We would stress that patients still need their local pharmacist for counseling, safety, and the full range of health care services they provide,” he explained.
Pharmacists are frequently enough the most accessible healthcare professionals, providing medication counseling, identifying potential drug interactions, administering vaccinations, and offering chronic disease management support. They are integral to ensuring medication adherence and optimizing patient outcomes.
The concern is that a system solely reliant on online drug shopping, without the guidance of a pharmacist, could lead to medication errors, adverse drug events, and a decline in overall patient safety. A 2018 study published in the Journal of the American Pharmacists Association found that community pharmacists intervene to prevent potential medication errors an average of 1.3 times per day.https://doi.org/10.1016/j.japh.2018.04.003 This level of personalized care is difficult to replicate in a purely digital environment.
The Need for Broader PBM Reform: Congressional Action is Key
Hoey emphasized that the administration’s plan, while a step in the right direction, is not a complete solution. He urged Congress to pass bipartisan legislation aimed at broader PBM reform. Several bills currently under consideration address issues such as:
* PBM Transparency: requiring PBMs to disclose more detailed details about their pricing practices and rebate arrangements.
* Stoping Spread pricing: Preventing PBMs from charging health plans more for a drug than they reimburse pharmacies. This practise, known as “spread pricing,” allows PBMs to pocket the difference, driving up costs for insurers and ultimately, patients.
* Fair Pharmacy Reimbursement: Ensuring that pharmacies are reimbursed fairly for dispensing medications, preventing situations where reimbursement rates are below the cost of acquisition.
the Pharmacy Benefit Manager Transparency Act of 2023 (H.R.1577/S.1285), for example, aims to increase transparency in PBM operations and prohibit unfair practices. [https://www.congress.gov/bill/1
